Try our Advanced Search for more refined results

Amgen Inc. et al v. Sanofi et al

  1. March 16, 2026

    Amgen And Sanofi End Repatha IP Fight Heard By Justices

    Amgen Inc. and Sanofi have settled patent litigation over competing cholesterol drugs Repatha and Praluent, more than two years after they dueled at the U.S. Supreme Court, Sanofi confirmed Monday.

  2. March 03, 2025

    Sanofi Grilled By Judge Over $1.2M In Amgen Patent Saga

    A federal judge in Delaware has told lawyers for Sanofi to rethink some of a $1.2 million costs bid, pointing to issues he had with the "bells and whistles" in litigation costs the French pharmaceutical giant had proposed after its successful defense of a decade-long patent fight by Amgen over cholesterol medication.

  3. August 29, 2019

    Amgen Cholesterol Drug Patents Nixed, Undoing Jury Verdict

    French drugmaker Sanofi scored a win Wednesday when a Delaware federal judge invalidated patents related to rival Amgen Inc.'s cholesterol-lowering drug Repatha, upending a February jury verdict that had gone largely in Amgen's favor.

  4. February 25, 2019

    Amgen's Cholesterol Drug Patents Are Valid, Jury Says

    Patents related to Amgen Inc.'s cholesterol-lowering drug Repatha survived a challenge by rival pharmaceutical company Sanofi when a Delaware federal jury found largely in Amgen's favor Monday.

  5. January 09, 2017

    Sanofi Vows Appeal After Drug Injunction Stay Is Denied

    Sanofi and its Regeneron Pharmaceuticals on Monday lost a bid to stay a permanent injunction of cholesterol-lowering drug Praluent ordered by a Delaware federal judge in a patent infringement suit brought by Amgen Inc., though the company has pledged to take the case to the Federal Circuit.

  6. January 05, 2017

    Amgen Wins Injunction On Sale Of Sanofi's Cholesterol Drug

    Sanofi and Regeneron Pharmaceuticals must stop selling the cholesterol-lowering drug Praluent after a Delaware federal judge entered a permanent injunction in favor of Amgen Inc. on Thursday in a patent infringement suit brought by Amgen that saw a jury victory last year.

  7. January 03, 2017

    Jury Verdict Upheld In Amgen Cholesterol Drug Patent Row

    An effort by drugmaker Sanofi to reverse a March jury verdict upholding cholesterol drug patents held by rival Amgen died Tuesday when a Delaware federal judge denied Sanofi's motions for judgment as a matter of law and for a new trial.

  8. May 24, 2016

    Sanofi Wants Jury Verdict Axed In Amgen Drug Patent Row

    Sanofi urged a Delaware federal judge Monday to toss a jury's verdict finding rival Amgen's cholesterol drug patents valid and order a new trial or enter judgment against Amgen in its infringement row, saying the court erred in excluding evidence and throwing out Sanofi's obviousness defense.

  9. May 13, 2016

    Sanofi Says Evidence Doesn't Justify Verdict In Patent Suit

    Sanofi-Aventis and Regeneron Pharmaceuticals Inc. pushed again Thursday for a Delaware federal judge to rule that the claims of two Amgen Inc. patents for a cholesterol drug were overbroad and insufficiently described after a jury found they were valid, saying the evidence admitted does not support the jury's findings..

  10. April 27, 2016

    Amgen Urges Ban On Cholesterol Drug Sales After Patent Win

    Amgen Inc. urged a Delaware federal judge to levy a permanent injunction barring Sanofi SA and Regeneron Pharmaceuticals Inc. from selling cholesterol drug Praluent after a jury found Amgen's patents for the drug valid, according to a redacted filing Wednesday.